National Cancer Center;Nippon Zoki Pharmaceutical Co., Ltd.
发明人:
申请号：
EP18816986.6
公开号：
EP3639821A1
申请日:
2018.06.12
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
An object of the present invention is to provide a carcinogenesis inhibitor having no side effect and having an excellent effect by oral administration.A carcinogenesis inhibitor of the present invention containing a hydantoin derivative or a pharmaceutically acceptable salt thereof as an active ingredient shows an inhibiting action for polyp formation and for cell proliferation, and has no side effect and highly safe whereby it is very highly useful as a pharmaceutical agent and a food such as supplement which prevent the occurrence and progress of cancer, inhibits the recurrence and metastasis of cancer and further achieves the therapeutic effect.
